Abstract | BACKGROUND: MATERIALS AND METHODS: RESULTS: Two of seven patients achieved an objective response, including one durable complete response and one partial response at a single time point. Both responding patients had germ cell tumors. Treatment with brentuximab vedotin was generally well tolerated. CONCLUSION: IMPLICATIONS FOR PRACTICE: This case series of seven patients with relapsed or refractory CD30-expressing germ cell tumors (GCTs) or sex cord stromal tumors demonstrates that brentuximab vedotin has activity against GCTs and is well tolerated in heavily pretreated patients with these aggressive tumor types. One patient achieved a complete response that has been durable for almost 4 years since the discontinuation of treatment with brentuximab vedotin. Therefore, brentuximab vedotin may be a valuable option for physicians who care for this difficult-to-treat patient population.
|
Authors | Costantine Albany, Lawrence Einhorn, Lawrence Garbo, Thomas Boyd, Neil Josephson, Darren R Feldman |
Journal | The oncologist
(Oncologist)
Vol. 23
Issue 3
Pg. 316-323
(03 2018)
ISSN: 1549-490X [Electronic] England |
PMID | 29222199
(Publication Type: Case Reports, Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © AlphaMed Press 2017. |
Chemical References |
- Antineoplastic Agents
- Immunoconjugates
- Immunologic Factors
- Ki-1 Antigen
- Brentuximab Vedotin
|
Topics |
- Adult
- Antineoplastic Agents
(administration & dosage)
- Brentuximab Vedotin
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Humans
- Immunoconjugates
(administration & dosage)
- Immunologic Factors
(administration & dosage)
- Ki-1 Antigen
(metabolism)
- Male
- Middle Aged
- Neoplasm Metastasis
- Neoplasms, Germ Cell and Embryonal
(drug therapy, pathology)
- Remission Induction
- Sex Cord-Gonadal Stromal Tumors
(drug therapy, pathology)
- Treatment Outcome
- Young Adult
|